Cytomel (Liothyronine) Cost in South Carolina 2026

What Liothyronine Is and Why South Carolina Patients Use It

Liothyronine is the synthetic form of triiodothyronine (T3), the biologically active thyroid hormone. The FDA approved Pfizer's brand Cytomel decades ago, and generic versions are now widely manufactured. Physicians prescribe it for hypothyroidism, myxedema coma, and, controversially, as an adjunct when levothyroxine monotherapy leaves patients symptomatic despite normal TSH levels. A frequently cited 1999 study by Bunevicius et al. in the New England Journal of Medicine (N=33) found that partial substitution of T4 with T3 improved mood and neuropsychological function in hypothyroid patients, reigniting interest in combination therapy [1].

South Carolina has roughly 5.3 million residents. Hypothyroidism affects approximately 4.6% of the U.S. population aged 12 and older according to NHANES data published through the NIH [2], translating to an estimated 240,000 South Carolinians who carry a thyroid diagnosis. A subset of those patients either cannot tolerate levothyroxine alone or have persistent symptoms despite adequate T4 replacement, making liothyronine a relevant second-line option for thousands of SC residents each year.

The drug is taken orally once or twice daily. Its short half-life (roughly 2.5 days, compared with levothyroxine's 7 days) means missed doses produce faster symptom recurrence [3]. That pharmacokinetic profile also means the dose must be split when target daily amounts exceed 25 mcg, to avoid peak-related palpitations [4].

2026 Cash-Pay Price for Liothyronine in South Carolina

Generic liothyronine costs approximately $35 per month at South Carolina retail pharmacies in 2026. That figure reflects the average cash-pay price across major chains and independent pharmacies statewide. Pfizer's branded Cytomel carries a manufacturer list price of approximately $120 per month. The gap between those two numbers is the single most actionable piece of cost information for uninsured or underinsured SC patients.

Price varies by tablet strength. A 30-day supply of 25 mcg tablets (one tablet daily) typically runs $28 to $40 at SC chains. The 5 mcg and 50 mcg strengths may cost slightly more per unit dose due to lower dispensing volume. GoodRx and similar discount platforms can reduce the generic price further, sometimes to $18 to $22 per month at specific SC pharmacies. Always compare prices at the point of pickup because pharmacy acquisition costs differ across the Midlands, Lowcountry, and Upstate regions.

The FDA's Orange Book lists multiple approved generic liothyronine manufacturers, including Mylan (Viatris), Lannett, and Westminster Pharmaceuticals [5]. Switching between generics mid-therapy is generally discouraged by the American Thyroid Association because small bioavailability differences across manufacturers may shift TSH values [6]. Ask your SC pharmacist to lock in one manufacturer when filling ongoing refills.

South Carolina Medicaid Coverage for Liothyronine

South Carolina Medicaid does not cover liothyronine (Cytomel or generic) for hypothyroidism adjunct therapy. This is a hard formulary exclusion, not a prior-authorization pathway. SC Healthy Connections Medicaid covers levothyroxine as the preferred thyroid replacement agent, consistent with most state Medicaid programs that follow cost-effectiveness tier structures [7].

SC Medicaid does maintain a medical exception process. A prescriber may submit a prior-authorization request arguing medical necessity if the patient has documented intolerance to levothyroxine or a clinical condition (such as thyroid cancer management requiring suppressive therapy) where liothyronine use is supported by evidence. The approval rate for such exceptions is not publicly reported by SCDHHS, but the pathway exists. The prescriber must document the clinical rationale in writing and typically must show that levothyroxine was tried and failed.

Dual-eligible patients (Medicare plus Medicaid) should check their Part D plan separately. Medicare Part D covers liothyronine on several formularies at Tier 1 or Tier 2, though deductible phases affect out-of-pocket cost before coverage kicks in. The CMS formulary search tool at cms.gov allows beneficiaries to check specific plan coverage before enrollment [8].

Is Compounded Liothyronine Legal in South Carolina?

Compounded liothyronine is legally available in South Carolina through state-licensed 503A pharmacies. This is patient-specific compounding, meaning a licensed prescriber must write a prescription for an individual patient. The compound cannot be manufactured in bulk and sold without a prescription.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs these pharmacies [9]. South Carolina's Board of Pharmacy enforces state compounding regulations that align with USP 795 standards for non-sterile preparations. Liothyronine tablets or capsules in non-commercially available strengths (for example, 12.5 mcg or 7.5 mcg) are among the most common compounds prepared under this framework.

The cost of compounded liothyronine from a SC 503A pharmacy runs approximately $40 per month, slightly above the generic retail average of $35 per month. The premium reflects custom compounding labor and quality-testing costs. Some patients choose compounded formulations specifically to obtain sustained-release or slow-release liothyronine capsules, which are not FDA-approved but are theoretically designed to smooth the T3 peak. The evidence base for SR-T3 is limited. A systematic review available through PubMed found insufficient data to recommend sustained-release formulations over immediate-release liothyronine, and the American Thyroid Association's 2014 guidelines noted that no clinical trials had validated SR-T3 preparations [6].

503B outsourcing facilities, which manufacture sterile or large-batch compounds, are subject to FDA oversight and are currently not a meaningful source of oral liothyronine in SC. Patients should verify any compounding pharmacy's license status through the SC Board of Pharmacy's online lookup [10].

Insurance Coverage for Cytomel and Generic Liothyronine in South Carolina

Private insurance plans sold in South Carolina generally cover generic liothyronine, though tier placement and prior-authorization requirements differ by plan. Most commercial formularies place generic liothyronine on Tier 1 (preferred generic) with a $0 to $15 copay after deductible. Brand-name Cytomel, if not step-therapy compliant, may require a prior authorization demonstrating that the generic was inadequate [11].

ACA marketplace plans sold through the SC exchange at healthcare.gov must cover prescription drugs, but the specific formulary is plan-specific. Blue Cross Blue Shield of South Carolina, the state's largest individual-market insurer, includes generic liothyronine on its preferred drug list. Medically reviewed prior-authorization criteria apply to the brand.

Employer-sponsored plans follow their pharmacy benefit manager's (PBM) national formulary. Express Scripts and CVS Caremark, the two dominant PBMs serving SC employers, list generic liothyronine as a preferred Tier 1 drug. The practical implication: most SC employees with job-based insurance pay a $5 to $20 copay per 30-day fill or $10 to $45 for a 90-day supply at mail order.

How to Get the Lowest Price on Liothyronine in South Carolina

Generic liothyronine is already inexpensive, but specific strategies reduce cost further for SC patients.

Use a GoodRx or similar coupon. GoodRx coupons for generic liothyronine 25 mcg (30 tablets) show prices as low as $4 to $12 at Walmart, Costco, and Kroger pharmacies in SC. These coupons cannot be combined with insurance but are often better than the cash price at non-discount chains.

Ask for a 90-day supply. Many SC pharmacies and all major mail-order pharmacies dispense 90-day supplies at roughly 2.5 times the 30-day price, saving about 17% per dose. A patient paying $35 per month drops to approximately $88 per quarter.

Check the manufacturer savings program. Pfizer does not offer a widely accessible savings card for Cytomel to cash-pay patients in the way GLP-1 manufacturers do, but patient assistance programs (PAPs) are available for qualifying low-income patients. The NeedyMeds database lists current PAP eligibility thresholds [12].

Consider telehealth prescribing. SC allows telehealth prescribing of liothyronine, which avoids an in-person specialist visit costing $150 to $350 out-of-pocket. A telehealth thyroid consultation through a licensed SC prescriber typically runs $50 to $150 and can generate the prescription needed for pharmacy filling.

Split higher-strength tablets if safe. A prescriber may authorize tablet splitting of scored 25 mcg tablets to achieve a 12.5 mcg dose, cutting per-dose cost by half. This is a clinical decision, not a pharmacist recommendation, and requires explicit prescriber approval.

Telehealth Prescribing of Liothyronine in South Carolina

South Carolina permits telehealth prescribing of non-controlled medications including liothyronine. The SC Telemedicine Act and the SC Board of Medical Examiners both support synchronous audio-video encounters as sufficient to establish the prescriber-patient relationship required for a new prescription [13].

Liothyronine is not a controlled substance under the DEA scheduling system. That means telehealth prescribers in SC face none of the Ryan Haight Act restrictions that complicate telehealth prescribing of stimulants or opioids. A licensed SC physician, nurse practitioner, or physician assistant can evaluate a patient via video, review prior thyroid labs, and send a liothyronine prescription to any SC retail or mail-order pharmacy.

HealthRX connects SC patients with board-certified clinicians who review TSH, free T3, free T4, and clinical symptom burden before prescribing. Most SC labs including LabCorp and Quest Diagnostics process thyroid panels within 24 to 48 hours at cash-pay prices of $30 to $60 without insurance [14]. That rapid turnaround makes telehealth-initiated liothyronine therapy logistically straightforward for most SC residents.

Follow-up monitoring after starting liothyronine typically involves repeating TSH and free T3 at 6 to 8 weeks. The Endocrine Society's clinical practice guidelines recommend against using TSH alone to monitor combination T4/T3 therapy, noting that free T3 levels must also be checked to avoid supraphysiologic T3 exposure [15]. Patients should ensure their follow-up lab order includes free T3 specifically, not just TSH.

Clinical Context: When Liothyronine Is Prescribed

Liothyronine is not first-line therapy for hypothyroidism. The standard of care remains levothyroxine (LT4) monotherapy. The American Thyroid Association's 2014 management guidelines state that LT4 monotherapy "remains the standard of care for hypothyroidism" [6]. Liothyronine enters clinical consideration in three main scenarios.

First, patients with persistent symptoms despite normal TSH on LT4 alone. The deiodinase enzyme pathway that converts T4 to T3 is genetically variable. Patients carrying specific DIO2 polymorphisms may convert T4 to T3 less efficiently, potentially benefiting from direct T3 supplementation. A 2019 study published in Thyroid (N=45) found that DIO2 Thr92Ala polymorphism carriers reported improved wellbeing on combination LT4/LT3 therapy compared with LT4 alone [16].

Second, myxedema coma. IV liothyronine or LT4 remains the acute treatment standard in this thyroid emergency. SC hospitals with ICU capability stock IV preparations.

Third, thyroid cancer management. After total thyroidectomy, patients undergoing radioiodine ablation may be switched temporarily from LT4 to liothyronine because LT3's shorter half-life allows faster TSH elevation before ablation, without the prolonged hypothyroid state that LT4 withdrawal causes [17].

The typical starting dose for adjunct liothyronine in combination therapy is 5 mcg to 12.5 mcg once or twice daily, added while reducing the LT4 dose proportionally. Most combination protocols reduce LT4 by 50 mcg for every 12.5 mcg of LT3 added, based on the approximate 4:1 T4-to-T3 potency ratio [6].

Safety Considerations for Liothyronine Users in South Carolina

Liothyronine's short half-life creates sharper peak plasma concentrations than levothyroxine. This characteristic increases the risk of transient cardiac effects at higher doses. The FDA prescribing information for liothyronine warns of the potential for angina, arrhythmia, and myocardial infarction, particularly in patients with underlying coronary artery disease [18].

South Carolina has a cardiovascular disease burden above the national average. According to the CDC, SC's heart disease death rate is approximately 193 per 100,000 residents, above the U.S. average of 173 per 100,000 [19]. That elevated baseline means SC prescribers should apply extra caution when initiating liothyronine in patients over 60 or those with known cardiac history.

Bone density is a secondary concern. Excess thyroid hormone suppresses TSH and accelerates bone turnover. A meta-analysis in the Journal of Bone and Mineral Research found that subclinical hyperthyroidism increased hip fracture risk by approximately 28% (RR 1.28 to 95% CI 1.07 to 1.52) [20]. Patients on combination LT4/LT3 therapy should have periodic bone density monitoring if TSH is consistently suppressed below 0.5 mIU/L.

Drug interactions in the SC patient population are relevant. Calcium carbonate, ferrous sulfate, and cholestyramine, all common in SC's older rural population, significantly reduce liothyronine absorption when taken within 4 hours of the thyroid dose. Patients should be counseled to separate these agents [18]. Warfarin anticoagulation effect is potentiated by liothyronine, requiring INR monitoring after any dose change [18].

Comparing Liothyronine to Levothyroxine: Cost and Clinical Trade-offs

Levothyroxine costs considerably less than liothyronine. Generic levothyroxine (Synthroid equivalent) runs $4 to $10 per month at most SC pharmacies, compared with $35 per month for generic liothyronine. South Carolina Medicaid covers levothyroxine; it does not cover liothyronine. That cost differential is relevant for patients weighing whether to request combination therapy.

From a clinical standpoint, the evidence for combination therapy over LT4 monotherapy is mixed. The Bunevicius et al. NEJM trial showed benefit [1], but multiple subsequent randomized trials and a 2019 Cochrane-style systematic review found no statistically significant quality-of-life advantage for most patients [21]. The Endocrine Society's position, as stated in their 2012 clinical practice guideline, is that "evidence is insufficient to recommend the routine use of combination T4/T3 therapy" [22].

That does not mean combination therapy is wrong for individual patients. It means the decision should be individualized, with shared decision-making between patient and prescriber, after a documented trial of optimized LT4 monotherapy. SC telehealth clinicians at HealthRX follow this sequence: optimize LT4 dose first, confirm free T4 in upper half of normal range, assess symptom persistence, then consider T3 addition if symptoms remain and cardiac and bone risk factors are acceptable.